Compare CYTK & LW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | LW |
|---|---|---|
| Founded | 1997 | 1950 |
| Country | United States | United States |
| Employees | N/A | 10100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 7.0B |
| IPO Year | 2004 | 2016 |
| Metric | CYTK | LW |
|---|---|---|
| Price | $61.52 | $40.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 7 |
| Target Price | ★ $88.50 | $56.14 |
| AVG Volume (30 Days) | 1.8M | ★ 2.2M |
| Earning Date | 05-05-2026 | 04-01-2026 |
| Dividend Yield | N/A | ★ 3.74% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.90 |
| Revenue | ★ $13,368,000.00 | N/A |
| Revenue This Year | $8.73 | $4.23 |
| Revenue Next Year | $309.93 | N/A |
| P/E Ratio | ★ N/A | $45.12 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.31 | $39.69 |
| 52 Week High | $70.98 | $67.07 |
| Indicator | CYTK | LW |
|---|---|---|
| Relative Strength Index (RSI) | 45.86 | 30.08 |
| Support Level | $59.13 | $39.79 |
| Resistance Level | $65.72 | $57.57 |
| Average True Range (ATR) | 2.57 | 1.42 |
| MACD | 0.03 | -0.50 |
| Stochastic Oscillator | 49.44 | 5.91 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Lamb Weston is North America's largest and the world's second-largest producer of branded and private-label frozen potato products, both by volume and value. The company's portfolio is anchored by french fries, but it also sells sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. Roughly two thirds of revenue comes from its home market of North America, with none of the other 100 countries the company sells into representing a significant share. McDonald's is Lamb Weston's single-largest customer at 15% of fiscal 2025 sales, with no other company representing more than 10%. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.